ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

174
Analysis
Health Care • South Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
•19 Jun 2020 21:54

Trading Strategy for SK Biopharm Post IPO Pricing

SK Biopharm announced its stellar IPO book building results today. The IPO price has been confirmed at 49,000 won, which is at the high end of the...

Logo
632 Views
Share
bearish•Aproele
•19 Jun 2020 14:34

Aproele IPO Valuation Analysis

To value Aproele, we used an 18.2x P/E multiple based on our 2021 net profit estimate of 8.9 billion won. The valuation multiple of 18.2x was...

Logo
480 Views
Share
•17 Jun 2020 02:00

SK Biopharmaceuticals Valuation Issues

One of the most debated issues during the book-building for SK Biopharm must be valuation.The bankers took an incredibly simple approach here. They...

Logo
502 Views
Share
bearish•SK Inc
•15 Jun 2020 20:42

SK Holdings: Time to Take Profits

Given the tremendous recent outperformance of SK Holdings, we believe this is a good time to take some profits on this stock. SK Holdings (034730...

Logo
557 Views
Share
•15 Jun 2020 12:13

SK Biopharm Valuation Analysis (What Is the Market Implying from SK Holdings?)

In this insight, we provide a valuation analysis of SK Biopharmaceuticals (BIO SK).Bullish Case Valuation - If we take a bullish case valuation...

Logo
537 Views
Share
x